UroAlerts - Prostate Cancer Weekly

October 22, 2024

Videos

Peer-to-Peer Clinical Conversations

EMBARK Trial: Age-Stratified Analysis of Enzalutamide in High-Risk Biochemically Recurrent Prostate Cancer - Neal Shore

Neal Shore

Zach Klaassen interviews Neal Shore about the EMBARK trial's post hoc analysis by age.

Advanced Prostate Cancer: Understanding Out-of-Pocket Medication Costs - Daniel Joyce

Daniel Joyce

Daniel Joyce discusses the financial impact of advanced prostate cancer treatments on patients.

Beyond the Abstracts

External Validation and Comparison of Magnetic Resonance Imaging-Based Risk Prediction Models for Prostate Biopsy Stratification - Beyond the Abstract

Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set - Beyond the Abstract

Conference Coverage

ASTRO 2024: Examination of Decipher® Prostate Genomic Classifier in Patients with De Novo Metastatic Disease from a Large Scale Real-World Clinical and Transcriptomic Data Linkage

ASTRO 2024: A Validation Study on the Impact of Decipher® Testing on Treatment Recommendations in African American and Non-African American Men with Prostate Cancer (VANDAAM STUDY)

ASTRO 2024: Impact of Hyaluronic Acid Rectal Spacer Quality Score and Fischer-Valuck Spacer Symmetry Score on Rectal Dosimetry and Acute and Late Gastrointestinal Toxicity Outcomes – An Australian Experience

ASTRO 2024: EMPIRE-2: Volumetric Changes and Acute Toxicity with 68Ga PSMA versus 18F-Fluciclovine PET/CT Guided Post-Prostatectomy Radiation: Final Analysis of a Randomized Trial

ASTRO 2024: MRI-Guided versus CT-Guided SBRT for Prostate Cancer: 2-Year Outcomes from the MIRAGE Randomized Clinical Trial

Physician-Scientist Review Articles

Metastasis-Directed Therapy in Oligometastatic Hormone-sensitive Prostate Cancer: New Frontiers in Advanced Prostate Cancer

Articles

Editor Selected Abstracts and Commentaries

Prostate Cancer

Prostate-specific Membrane Antigen (PSMA) Spatial Biomarker: Standardized Positron Emission Tomography Disease Maps Provide Accurate Prediction of Overall Survival in Prostate Cancer.

Sequential [177Lu]Lu-PSMA-617 and Docetaxel Versus Docetaxel in Patients with Metastatic Hormone-Sensitive Prostate Cancer (UpFrontPSMA): A Multicentre, Open-Label, Randomised, Phase 2 Study - Beyond the Abstract

Optimizing risk stratification for intermediate-risk prostate cancer - the prognostic value of baseline health-related quality of life.

Multivariable models of outcomes with [177Lu]Lu-PSMA-617: analysis of the phase 3 VISION trial.

Comparison of Transatlantic Recommendations for Prostate Gland Evaluation with MRI after Focal Therapy (TARGET) and Prostate Imaging after Focal Ablation (PI-FAB) for Detecting Recurrent Prostate Cancer at Prostate MRI.

Comparative efficacy and safety of talazoparib plus enzalutamide and other first-line treatments for metastatic castration-resistant prostate cancer.

Castration Levels of Testosterone Results in Atrophy of Androgen-Sensitive Perineal Muscles: A Potential Biomarker for Male Hypogonadism.

Novel Radiopharmaceuticals and Future of Theranostics in Genitourinary Cancers

Peripheral Blood IFN Responses to Toll-Like Receptor 1/2 Signaling Associate with Longer Survival in Men with Metastatic Prostate Cancer Treated with Sipuleucel-T

Diet Quality, Dietary Inflammatory Potential, and Risk of Prostate Cancer Grade Reclassification.

Urologic oncology case volume among early career urologists: An analysis of certification data from the American board of urology between 2003 and 2019.

All that glitters is not gold: high uptake on PSMA PET in non-prostate cancers does not mean that treatment with [177Lu]Lu-PSMA-radioligand will be successful.

Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management - Beyond the Abstract

A Targeted Methylation-Based Multicancer Early Detection Blood Test Preferentially Detects High-Grade Prostate Cancer While Minimizing Overdiagnosis of Indolent Disease - Beyond the Abstract

Relugolix Plus Enzalutamide For Metastatic Hormone-Sensitive Prostate Cancer: A Case Report.

Extraperitoneal Robot-Assisted Radical Prostatectomy with the Hugo™ RAS System: Initial Experience at a High-Volume Robotic Centre.

Simultaneous Autophagy and Androgen Receptor Inhibition in a Prostate Cancer Xenograft Model.

Drug Interactions between Androgen Receptor Axis-Targeted Therapies and Antithrombotic Therapies in Prostate Cancer: Delphi Consensus.

Prostate-specific Membrane Antigen Positron Emission Tomography Before Reaching the Phoenix Criteria for Biochemical Recurrence of Prostate Cancer After Radiotherapy: Earlier Detection of Recurrences.

Sleep and health improvement programme (SHIP) for patients with prostate cancer and caregivers.

Revisiting HER2 in Prostate Cancer from an Inclusive Perspective: From Biomarkers to Omics.

Targeted Prostate Health Checks, a novel system to identify men with prostate cancer-A pilot study.

Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review.

Aerobic Physical Activity and Depression Among Patients With Cancer A Systematic Review and Meta-Analysis

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer.

Copper-67 SAR-bisPSMA Updates

Machine learning and explainable artificial intelligence to predict pathologic stage in men with localized prostate cancer.

External Validation of a Previously Developed Deep Learning-based Prostate Lesion Detection Algorithm on Paired External and In-House Biparametric MRI Scans.

Accuracy of the LaserSAFE technique for detecting positive surgical margins during robot-assisted radical prostatectomy: blind assessment and inter-rater agreement analysis.

General Obesity and Prostate Cancer in Relation to Abdominal Obesity and Ethnic Groups: A US Population-Based Cross-Sectional Study.

Investigating the pattern of prostate specific antigen screening among E-cigarette smokers within the behavioral risk factor surveillance system.

Prior Local Therapy and First-Line Apalutamide in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of the SPARTAN Randomized Clinical Trial.

Enzalutamide in metastatic hormone-sensitive prostate cancer: A plain language summary of the ARCHES and ENZAMET follow-up studies.

Identification of a 5-gene signature panel for the prediction of prostate cancer progression.

Matched-pair analysis of mCRPC patients receiving 177Lu-labeled PSMA-targeted radioligand therapy in a 4-week versus 6-week treatment interval.

Association between smoking and prostate cancer survivors' long-term quality of life and function: an analysis of the CEASAR (Comparative Effectiveness Analysis of Surgery and Radiation) study.

How Can Participant Experience of Quality-of-Life Research Be Improved in Cancer Research: Views of the Patient and Public Involvement Representatives from the STAMPEDE2 Prostate Cancer Trial - Beyond the Abstract

Prostate Cancer Early Detection in the European Union and UK - Beyond the Abstract

Local Salvage Therapies in Patients with Radio-Recurrent Prostate Cancer Following External Beam Radiotherapy: A Systematic Review and Meta-Analysis - Beyond the Abstract

Prediction of Undetectable Circulating Tumor DNA by Comprehensive Genomic Profiling Assay in Metastatic Prostate Cancer: The SCRUM-Japan MONSTAR SCREEN Project - Beyond the Abstract

CONNECT WITH US

Questions or Comments? Email us at editors@urotoday.com

Digital Science Press, LLC
2011 Phaethon Lane,
Reno, NV 89523

You are receiving this email because you have chosen to receive emails from UroToday.

Add us to your address book View this email as a web page Forward to a colleague Manage your subscriptions Unsubscribe

Copyright ©2024 Digital Science Press, LLC